Scientists at Genzyme Corporation target leukemia

11-07-2006

Scientists discuss in "Tumor models for efficacy determination" new findings in leukemia. According to recent research from the United States, "The first in vivo tumor models were developed in the mid-1960s. These models were mouse leukemia models grown as ascites."

"The growth pattern was like that of bacteria in vivo and therefore it was possible to apply similar mathematics of growth and response to these tumors as had been worked out for bacteria. Since the development of the murine leukemia models, investigators have devoted a large effort to modeling solid tumors in mice. There are now a variety of models including syngeneic mouse tumors and human tumor xenografts grown as s.c. nodules, syngeneic mouse tumors and human tumor xenografts grown in orthotopic sites, models of disseminated disease, "labeled" tumor models that can be visualized using varied technologies, and transgenic tumor models," wrote B.A Teicher and colleagues, Genzyme Corporation.

The researchers concluded: "Each of these types of models has advantages and disadvantages to the "drug hunter" searching for improved treatments."

Teicher and colleagues published their study in Molecular Cancer Therapeutics (Tumor models for efficacy determination. Molecular Cancer Therapeutics, 2006;5(10):2435-43).

For additional information, contact B.A. Teicher, Genzyme Corporation, 1 Mountain Road, Framingham, MA 01701 U.S.

Publisher contact information for the journal Molecular Cancer Therapeutics is: American Association Cancer Research, 615 Chestnut St., 17TH Floor, Philadelphia, PA 19106-4404, USA.

Keywords: United States, Mountain Road, Biotechnology Business, Biotechnology Company, Genzyme Corporation, Hematology, Leukemia, Oncology.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2006, Biotech Business Week via NewsRx.com.